Auvelity is not a stimulant. It is classified as a psychotherapeutic combination antidepressant, FDA-approved for treating major depressive disorder in adults and agitation associated with Alzheimer’s disease. Neither of its two active ingredients is a controlled substance. That said, one of its components has a chemical structure related to amphetamines, which is likely why this question comes up so often.
What Auvelity Actually Contains
Auvelity combines two drugs: dextromethorphan and bupropion. Dextromethorphan (the active ingredient in many over-the-counter cough suppressants) works primarily by blocking a specific receptor in the brain involved in glutamate signaling. Glutamate is the brain’s main excitatory chemical messenger, and modulating it appears to have antidepressant effects through a pathway completely different from traditional antidepressants.
Bupropion plays a dual role. On its own, it’s an established antidepressant that increases the activity of norepinephrine and dopamine in the brain. But in Auvelity, bupropion also serves a pharmacological purpose: it blocks the liver enzyme that would normally break down dextromethorphan too quickly, allowing dextromethorphan to reach and maintain effective levels in the body.
Why People Associate It With Stimulants
The confusion traces back to bupropion. Its chemical structure closely resembles diethylpropion, an appetite suppressant, and it belongs to a family of compounds related to phenylethylamines, the same broad chemical family that includes amphetamines. In animal studies, bupropion produces dose-related stimulant effects like increased activity and repetitive behaviors. In human studies comparing it to drugs of abuse, a single high dose of bupropion (400 mg) produced mild amphetamine-like effects on standardized addiction research scales, scoring somewhere between a placebo and actual amphetamine.
These properties are real but modest. Bupropion is not classified as a stimulant, not scheduled as a controlled substance, and has been prescribed as an antidepressant (under the brand name Wellbutrin) since the 1980s. It does increase dopamine activity, which is the same neurotransmitter system that stimulants target, but it does so as a relatively weak inhibitor of dopamine reuptake compared to actual stimulant medications.
Side Effects That Can Feel Stimulant-Like
Some of Auvelity’s side effects overlap with what you might expect from a stimulant, which can reinforce the impression that it is one. Insomnia, restlessness, agitation, and increased anxiety are all reported side effects. In rare cases, particularly in people with undiagnosed bipolar disorder, Auvelity can trigger manic episodes characterized by greatly increased energy, racing thoughts, reduced need for sleep, and excessive talking.
Auvelity can also raise blood pressure, another effect it shares with stimulant medications. Your blood pressure should be checked before starting treatment and monitored during it. These effects don’t make Auvelity a stimulant in pharmacological terms, but they do mean some people will experience an activating quality, especially in the early weeks of treatment.
The Amphetamine Drug Test Issue
One particularly confusing detail: Auvelity can cause a false positive for amphetamines on urine drug screening tests. This happens because standard immunoassay screens aren’t specific enough to distinguish bupropion’s chemical structure from amphetamines. A confirmatory test using gas chromatography or mass spectrometry will correctly identify bupropion and rule out actual amphetamine use. False positives can occur even after you stop taking the medication. If you’re subject to drug testing for work or any other reason, let the testing facility know you take Auvelity before the test.
How It Differs From Stimulants
Stimulant medications like those prescribed for ADHD work by flooding the brain with dopamine and norepinephrine quickly and powerfully. They are Schedule II controlled substances with recognized potential for dependence and abuse. Auvelity works through a fundamentally different primary mechanism: modulating glutamate signaling via its dextromethorphan component. The bupropion component does touch the dopamine system, but weakly by comparison, and its main job in this formulation is to keep dextromethorphan levels high enough to be therapeutic.
Neither ingredient in Auvelity is a controlled substance. It is not classified as having high abuse potential, and it is not in the same drug category as amphetamines, methylphenidate, or any other stimulant. The activating side effects some people experience are a feature of its pharmacology, not evidence that it belongs in a different drug class.